Parexel
Parexel is recorded as a service provider in 843 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 843 trials · Latest update first
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
Sponsor Astrazeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-Blind, 52-Week Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Nonsegmental Vitiligo
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- The study randomized 607 participants against a planned sample size of 600.
- Enrollment comprised 255 participants from North America, 172 from Europe, 139 from Asia, and 41 from the rest of the world.
- A February 2025 protocol amendment reduced the planned percentage of adolescent enrollment.
- A December 2023 amendment permitted adolescent enrollment in the United States.
- A May 2024 amendment required participants who discontinued study intervention to remain in the study for scheduled safety and efficacy follow-up.
- An August 2023 amendment updated endpoints in response to global regulatory feedback and revised target Fitzpatrick skin-type strata.
These findings describe the trial, not the service provider’s performance or responsibility.
An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Approximately 50% of the first 22 Part 1 participants experienced on-treatment ALT elevations, and protocol management criteria were amended because some elevations were prolonged.
- New enrollment was temporarily halted in December 2022 after significant ALT elevations were observed more frequently in Part 2 participants with screening or baseline HBsAg >10,000 IU/mL.
- Enrollment was not reopened because the sponsor discontinued further investment in its hepatitis B and D discovery and development programs.
- Part 2 open-label treatment was reduced to Week 96 and follow-up to 24 weeks under protocol amendment 5.
- Sustained HBV response was not collected or analyzed because follow-up was shortened and participants continued NA treatment during follow-up.
These findings describe the trial, not the service provider’s performance or responsibility.
KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis, followed by an open label extension phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the pediatric ORION-16 , ORION-13, ORION-20, or ORION-19 studies (VICTORION-PEDS-OLE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, roll-over study to assess long-term safety in subjects who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Parexel?
The 2026-10-09 snapshot links Parexel to 843 distinct CTIS trials. Recorded services include Regulatory services, Clinical monitoring, Data management, Safety reporting & pharmacovigilance, among 165 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Parexel?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Immunology, Respiratory, Haematological Malignancies. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Parexel conducted?
The linked trials record locations in 26 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Parexel delivered services.
What can this page tell me about Parexel's trial experience?
Browse 843 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 19 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 17 recorded name variants under Parexel. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- PAREXEL INTERNATIONAL (IRL) Limited
- PAREXEL International
- PAREXEL International Czech Republic s.r.o.
- PAREXEL International GmbH
- Parexel
- Parexel Bioanalytical Services Division
- Parexel China Co. Ltd.
- Parexel International
- Parexel International (IRL) Limited
- Parexel International Co. Ltd.
- Parexel International Corp.
- Parexel International Corporation
- Parexel International GmbH
- Parexel International Limited
- Parexel International Romania S.R.L.
- Parexel International S.R.L.
- Parexel International Services India Private Limited